Castle Biosciences says Mayo Clinic data show TissueCypher shifts Barrett’s surveillance intervals 55%

• Castle Biosciences disclosed new Mayo Clinic studies on its TissueCypher test in Barrett’s esophagus, with results already presented at Digestive Disease Week 2026 in Chicago.
• Research found molecular risk profiling with TissueCypher changed real-world surveillance plans for many patients versus approaches guided by traditional pathology, supporting more individualized follow-up timing.
• A separate analysis showed TissueCypher risk calls often diverged from a standard clinical risk model, with findings suggesting the molecular test could better separate patients needing closer monitoring or earlier intervention from those suitable for less intensive surveillance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605040700PR_NEWS_USPR_____DA49752) on May 04, 2026, and is solely responsible for the information contained therein.